DoD contract for Terumo, 1/14

January 2014—Terumo BCT has been awarded a U.S. Department of Defense cost-share contract worth up to $29.9 million to advance the Mirasol system for the treatment of donated whole blood used in emergency transfusions to deployed military personnel.

Terumo is working with the U.S. Army Medical Research and Material Command to develop an FDA-approved whole blood pathogen-reduction device. The Mirasol system treats blood with a combination of riboflavin (vitamin B2) and ultraviolet light to render a broad range of disease-causing viruses, bacteria, and parasites less pathogenic.

The new cost-share contract expands Terumo’s Mirasol system development efforts initiated with the Department of Defense in 2007.

Terumo BCT, 303-231-4357